Molecular Enzymology and Drug Targets

  • Journal h-index: 4
  • Journal CiteScore: 0.47
  • Journal Impact Factor: 0.33
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • Publons
  • Google Scholar
  • Secret Search Engine Labs
Share This Page
Recommended Webinars & Conferences


Delivery of Anti-Hiv Drugs of Targeting Strategies

Ankit Mishra*

Infection with the human immunodeficiency virus continues to be a leading cause of death worldwide. The current antiretroviral therapy has a number of drawbacks, including toxicity, drug-drug interactions, the development of drug resistance, the need for long-term drug therapy, poor bioavailability, and lack of access to tissues and reservoirs, even though it has significantly decreased AIDS-related morbidity and mortality. Recent anti-HIV therapeutic research has concentrated on developing drug delivery methods that are selectively targeted to host cells that are HIV-infected or at risk of becoming HIV-positive in order to get around these issues. In this context, a number of surface molecules with both viral and host cell cellular origins have been identified in recent years, which might allow for the targeted administration of drugs to HIV-infected individuals. In this review, we give a thorough overview of the need. Identifying novel viral and hostcell molecules for novel drug delivery systems, as well as the accomplishments and difficulties in doing so for targeted drug delivery of anti-HIV medications. Such customised anti-retroviral drug delivery strategies may open the door to the successful management and elimination of HIV in humans.


HIV; Aids; Targeted Drug delivery; Viral targets; Host targets

Published Date: 2023-02-28; Received Date: 2023-02-02